ARCHIVES

ODAC Clarifies Standards for Maintenance In Ovarian Cancer; Nixes Olaparib in 11-2 Vote

This article is from The Cancer Letter archive.

Vol. 40 No. 26 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

Caris Life Sciences Lays Off Estimated 20 Percent of Staff

October 24, 2014

Genetics Flexes Muscle At AACR Annual Meeting, Joint Session With ASCO On Genetic Charges

May 24, 1991

NCI Advisors Approve New Grant Program In Bone Metastasis

April 5, 2002

Clinton Declares Month of April Cancer Control Month

April 11, 1997

Senate Subcommittee Oks $850Million for Cancer; NCI Reveals How It Would Spend Fiscal 1978 Funds

June 18, 1976